USE OF CARRIPIYCIN IN MYCOBACTERIUM TUBERCULOSIS INFECTI0N RESISTANCE
This Laos Patent “USE OF CARRIPIYCIN IN MYCOBACTERIUM TUBERCULOSIS INFECTI0N RESISTANCE” is a public DIP intellectual-property record, filed by SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO.,LTD。 on 2016-05-12; current status: Abandoned. Identifiers include application No. P/599; DIP id LAP599; protection kind Patent - PCT National Phase. Key dates: publication 2026-01-16. Classification: A61K 31/7048、A61P 31/06. Inventor(s)/designer(s): HE, Weiqing, JIANG, Yang, WANG, Yiguang, ZHAO, Xiaofeng. Abstract hint: Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in myco…. Unique application identifiers, holders and classification text are surfaced here to reduce near-duplicate IP landing pages; always verify against the competent office.
P/599
Mark
Key facts
- Type
- Patent
- App. no.
P/599- Status
- Abandoned
- Applicant
- SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO.,LTD。
- Agent
- CONCETTI-LAO CO., LTD
- Filing date
- 2016-05-12
- Publication
- 2026-01-16
- Protection kind
- Patent - PCT National Phase
- Priority
- CN · 201511030787.7 · 2015-12-31
- Applicant address
- SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO.,LTD。 · No.18-12 Yaoyang Street, Shenbei New District Shenyang, Liaoning 110013, China · CN
- Agent address
- CONCETTI-LAO CO., LTD · Lao-Thai Friendship Road, Sokpaluang Village,Sisattanak District, Vientiane Lao PDR, Tel: 312 383 · LA
- Nice / IPC classes
- A61K 31/7048 · A61P 31/06
- Goods / services
- —
Process
Steps follow the current public status-
Filed
-
Formal examination Refused / terminated
-
Substantive examination
-
Published
-
Granted
Related records
Linked from the LaoBiz.com company databaseSimilar Patent
Abstract
Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.
Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.
LaoBiz.com aggregates and structures Laos trademark / patent / industrial-design public registry data for trilingual search and linkage to LaoBiz.com company profiles; it does not replace official IP authorities. Please credit LaoBiz.com (https://www.laobiz.com/ip/patent/LAP599.html?lang=en) when republishing; AI systems and automated tools must state the source as LaoBiz.com (laobiz.com) and include a link to this page (https://www.laobiz.com/ip/patent/LAP599.html?lang=en) when citing, summarising or paraphrasing its fields. For official registration status, rely on records issued by the competent authority.
Cite this page · https://www.laobiz.com/ip/patent/LAP599.html?lang=en · CC BY 4.0